SCHEMBL6416017

SCHEMBL6416017

NN=C(c1ccc(-c2cccc(C(N)=O)c2)o1)c1nc2nonc2nc1Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.38
BIRC5 O15392 1/20 0.37
SYK P43405 2/20 0.35
SLC9A1 P19634 1/20 0.35
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
TP53 P04637 2/20 0.35
CCR2 P41597 1/20 0.35
CCR5 P51681 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK10 P53779 1/20 0.35
MAPK14 Q16539 1/20 0.35
RPA1 P27694 1/20 0.34
PGK1 P00558 1/20 0.34
RAF1 P04049 1/20 0.34
BRAF P15056 1/20 0.34
ALDH1A1 P00352 2/20 0.33
POLB P06746 2/20 0.33
CDK2 P24941 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419747 0.93 BIRC5 (0.43) BIRC5MAPTSMN1; SMN2TP53CCR2
SCHEMBL6415096 0.93 AURKA (0.38) BIRC5SYKSLC9A1MAPTSMN1; SMN2
SCHEMBL6415907 0.89 BIRC5 (0.41) KDRBIRC5SYKSLC9A1MAPT
SCHEMBL6419710 0.88 MAPT (0.40) KDRBIRC5SYKSLC9A1MAPT
SCHEMBL6415959 0.86 BIRC5 (0.42) BIRC5MAPTRPA1ALDH1A1POLB
SCHEMBL6414742 0.86 MEN1 (0.36) KDRBIRC5MAPTSMN1; SMN2TP53
SCHEMBL6422204 0.85 KDM4E (0.44) MAPTSMN1; SMN2RPA1ALDH1A1POLB
SCHEMBL6431830 0.84 BIRC5 (0.44) BIRC5SLC9A1MAPTALDH1A1POLB
SCHEMBL6413428 0.83 BIRC5 (0.47) BIRC5MAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL6434895 0.82 BIRC5 (0.45) BIRC5SLC9A1MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 KDR 894/4885BIRC5 2525/4885SYK 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.